What Microdosing Actually Does: Mechanism and Its Limits At lower dose levels, GLP-1 medications may still influence appetite, insulin signaling, and digestion, but the metabolic effects become less predictable than they are at validated trial doses
Patients meeting the following criteria were excluded from the analysis: evidence of type 1 diabetes or pregnancy in the study period, missing age or sex data, initiation of another new glucose-lowering therapy on the index date, and use of any GLP-1RA in the baseline period
Results vary for each individual
However, the life-saving benefits of ART come with a metabolic cost, particularly for mitochondrial DNA (mtDNA)
Expanding coverage would make these products more accessible to underserved populations, particularly those disproportionately affected by obesity and diabetes